Question explored with the scientific record
Medicines for high blood pressure. Which ones actually reduce blood pressure.
The evidence shows many drug classes lower blood pressure, but the real question is which ones do it without trading one problem for another.
The retrieved studies are a thin sample of a vast literature. They do not cover long-term safety, head-to-head comparisons on hard outcomes like heart attack or death, or the critical question of how these drugs affect blood flow at the colloidal level. What they do show is that several classes produce measurable drops in office and ambulatory blood pressure over weeks to months.
Thiazide diuretics like hydrochlorothiazide (HCTZ) reduce systolic pressure by about 13-22 mmHg when added to another drug [6, 7, 8]. Low-dose HCTZ (12.5-25 mg) combined with an ARB or ACE inhibitor appears to avoid the worst metabolic side effects [7]. ACE inhibitors like perindopril and enalapril produce reductions of 10-18 mmHg [4, 5, 6]. ARBs like telmisartan and losartan show similar drops, around 10-14 mmHg [5, 9]. Calcium channel blockers like amlodipine also work, with combination therapy often beating monotherapy [10, 11].
The most interesting finding is about timing and add-on drugs. Bedtime dosing of one antihypertensive in resistant patients improved control rates from 13% to 21% and cut non-dipping patterns from 82% to 57% [1]. Spironolactone added to a failing regimen produced an extra 5.4 mmHg systolic drop in resistant hypertension [2]. The newer aldosterone synthase inhibitors (baxdrostat, lorundrostat) show placebo-adjusted reductions of 9-11 mmHg in resistant patients [12].
| Drug Class | Typical SBP reduction (mmHg) | Best use |
|---|---|---|
| Thiazide diuretic (low dose) | 13-22 (add-on) | First-line, especially with ARB/ACEi |
| ACE inhibitor | 10-18 | First-line, especially with diuretic |
| ARB | 10-14 | First-line, fewer side effects than ACEi |
| Spironolactone | 5-9 (add-on) | Resistant hypertension |
| Aldosterone synthase inhibitor | 9-11 (add-on) | Resistant, newer option |
The evidence is almost entirely short-term (weeks to months) and funded by manufacturers. No study here compares these drugs to lifestyle changes like weight loss, which a separate meta-analysis shows reduces systolic pressure by 4.4 mmHg for a 5 kg loss [3]. The absence of long-term safety data on blood sludging, zeta potential, or endothelial function is a gap these records cannot fill.
My call: Several drug classes clearly lower blood pressure in the short term. The best evidence supports low-dose thiazide diuretics, ACE inhibitors, and ARBs, often in combination. Timing matters: bedtime dosing improves control. But the evidence base is short-term and industry-funded, and the long-term effects on blood flow quality are unstudied. Confidence: moderate for short-term blood pressure reduction; low for long-term safety and net benefit.
Sources used 12
-
Effects of Time of Day of Treatment on Ambulatory Blood Pressure Pattern of Patients With Resistant Hypertension
This study investigates the effects of treatment timing on blood pressure patterns in patients with resistant hypertension, revealing that administering one antihypertensive drug at bedtime significantly improves blood pressure control and reduces the prevalence of non-dipping p…
DOI: 10.1161/01.hyp.0000172757.96281.bf -
Addition of Spironolactone in Patients With Resistant Arterial Hypertension (ASPIRANT)
The ASPIRANT trial demonstrated that the addition of 25 mg of spironolactone significantly reduces systolic blood pressure in patients with resistant arterial hypertension who are already on multiple antihypertensive medications.
DOI: 10.1161/hypertensionaha.111.169961 -
Influence of Weight Reduction on Blood Pressure
This meta-analysis of 25 randomized controlled trials involving 4874 participants demonstrates that a net weight reduction of 5.1 kg significantly reduces both systolic and diastolic blood pressure, highlighting the importance of weight loss in managing hypertension.
DOI: 10.1161/01.HYP.0000094221.86888.AE -
Dose-Dependent Antihypertensive Efficacy and Tolerability of Perindopril in a Large, Observational, 12-Week, General Practice-Based Study
The CONFIDENCE study demonstrates that perindopril, administered at doses of 4 and 8 mg daily, is effective and well-tolerated for managing hypertension in a real-world clinical setting, achieving significant blood pressure reductions and high patient compliance over a 12-week p…
DOI: 10.2165/11587000-000000000-00000 -
Impact of prolonged antihypertensive duration of action on predicted clinical outcomes in imperfectly adherent patients: comparison of aliskiren, irbesartan and ramipril
This study evaluates the impact of prolonged antihypertensive duration of action on predicted clinical outcomes in patients with imperfect adherence, comparing the effects of aliskiren, irbesartan, and ramipril on systolic blood pressure reduction and cardiovascular disease risk.
DOI: 10.1111/j.1742-1241.2010.02616.x -
Blood Pressure-Lowering Efficacy of Amiloride versus Enalapril as Add-On Drugs in Patients with Uncontrolled Blood Pressure Receiving Hydrochlorothiazide
This study compares the blood pressure-lowering efficacy of amiloride and enalapril as add-on treatments in patients with uncontrolled hypertension already receiving hydrochlorothiazide, finding that enalapril is more effective in reducing blood pressure.
DOI: 10.1080/10641960802441906 -
Low dose of hydrochlorothiazide, in combination with angiotensin receptor blocker, reduces blood pressure effectively without adverse effect on glucose and lipid profiles
This study demonstrates that a low dose of hydrochlorothiazide combined with candesartan effectively reduces blood pressure in patients with essential hypertension without adversely affecting glucose and lipid profiles.
DOI: 10.1007/s00380-012-0246-5 -
Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy
This study evaluates the antihypertensive efficacy and tolerability of valsartan combined with hydrochlorothiazide compared to monotherapy and placebo in patients with essential hypertension, demonstrating that combination therapy significantly reduces blood pressure more effect…
DOI: 10.1038/sj.jhh.1000718 -
Effects of telmisartan, hydrochlorothiazide and their combination on blood pressure and renal excretory parameters in spontaneously hypertensive rats
In SHRs, telmisartan 3 mg/kg plus HCTZ 10 mg/kg for five days produced larger BP reductions than telmisartan monotherapy, while HCTZ alone did not lower BP and combination treatment only raised BUN with some attenuation of K+ loss.
DOI: 10.3317/jraas.2001.013 -
Effects of Calcium Channel and Renin-Angiotensin System Blockade on Intravascular and Neurohormonal Mechanisms of Hypertensive Vascular Disease
A comprehensive review arguing that combined calcium-channel blockade and renin-angiotensin system blockade provides vascular benefits beyond brachial blood pressure by improving central arterial pressure, reducing arterial stiffness, and enhancing endothelial nitric oxide bioav…
DOI: 10.1038/ajh.2008.258 -
Combination antihypertensive therapy: Does it have a role in rational therapy?
A comprehensive review arguing that fixed-dose, low-dose antihypertensive drug combinations can improve blood pressure control and tolerability compared with sequential monotherapy, supported by cross-trial evidence across diuretics, ACE inhibitors, beta-blockers, and calcium an…
DOI: 10.1016/s0895-7061(97)00101-5 -
Aldosterone Synthase Inhibitors in Resistant Hypertension
This narrative review concludes that highly selective aldosterone synthase inhibitors (baxdrostat, lorundrostat) produce consistent, clinically meaningful blood pressure reductions in uncontrolled and resistant hypertension without clinically relevant cortisol interference, posi…
DOI: 10.58624/SVOAMR.2026.04.001